Qlucore and Clarivate partner to provide researchers with powerful and flexible omics data analysis and visualization

12 August 2021 - 15:15

Researchers will be able to make faster and more accurate analysis of experiment data with a workflow powered by Qlucore Omics Explorer and MetaCore™, a Cortellis™ solution.

Qlucore Omics Explorer’s next generation bioinformatics software will be the first step in data analysis and visualization, and through integration it enables the user to conduct further analysis with MetaCore’s high-quality, 100% manually curated drug development content, including comprehensive, validated pathway data. 

This combination will give researchers faster experimental results and data presentation in the optimal biological context. The tools are so easy to use that researchers will be better able to easily interpret and explore multi-omics data.

Qlucore Omics Explorer is the bioinformatics software for multi-omics analysis. Scientists can quickly analyze and visualize their experiment data. Adding additional knowledge from databases and the community is facilitated in several ways, and with the addition of the MetaCore integration more options will be available.

“The combination of Qlucore Omics Explorer and MetaCore will make it easier and faster for research scientists to obtain clear and validated results” says Carl-Johan Ivarsson, Qlucore President.

Gavin Coney, VP, Science Group Channels & Alliances at Clarivate, said: “At Clarivate we are committed to supporting the research community by providing trusted information and insights to accelerate the pace of innovation. Partnering with Qlucore will enhance the experience of researchers and aid the acceleration of scientific innovation.”

Provided by: MFN
Nasdaq First North GM (Sweden)
Qlucore AB
Qlucore makes it easier to analyze the huge amounts of complex data that are generated by innovations in the fields of genetics and proteomics. It is done by providing powerful visualization-based bioinformatics data analysis tools for research and precision diagnostics....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More